Idarubicin and liver function test abnormal Patient Reports February 12, 2012

Idarubicin Side Effects Report #4976182-X
Idarubicin side effect was reported by a Health Professional from AUSTRALIA on Mar 31, 2006. Female patient, 49 years of age, weighting 126.5 lb, was diagnosed with acute myeloid leukaemia and was treated with Idarubicin. After drug was administered, patient experienced the following side effects: liver function test abnormal, venoocclusive liver disease. Idarubicin dosage: 14 MG, 1 IN 1 D, INTRAVENOUS. During the same period patient was treated with CYTARABINE, ETOPOSIDE, AMPHOTERICIN B, MEROPENEM, TEICOPLANIN. Patient recovered.

Idarubicin Side Effects Report #4817558-0
Idarubicin side effect was reported by a Health Professional from AUSTRALIA on Oct 24, 2005. Male patient, 33 years of age, weighting 207.2 lb, was diagnosed with acute myeloid leukaemia and was treated with Idarubicin. After drug was administered, patient experienced the following side effects: anuria, atrial fibrillation , cardiac arrest , cardiac tamponade, haematemesis, hepatomegaly, international normalised ratio increased, liver function test abnormal, melaena. Idarubicin dosage: 19 MG (19 MG, CYCLICAL - DAILY), INTRAVENOUS. During the same period patient was treated with ETOPOSIDE, CYTARABINE. Patient died on 09/10/2005.

Idarubicin Side Effects Report #6094908-1
Idarubicin side effect was reported by a Health Professional from UNITED STATES on Dec 22, 2008. Male patient, child 3 years of age, weighting 35.27 lb, was diagnosed with acute myeloid leukaemia and was treated with Idarubicin. After drug was administered, patient experienced the following side effects: febrile neutropenia, liver function test abnormal. Idarubicin dosage: 12MG/M2, QD FOR A TOTAL OF E. Patient was hospitalized. Patient recovered.

Idarubicin Side Effects Report #5071665-9
Idarubicin side effect was reported by a Health Professional from AUSTRALIA on July 19, 2006. Male patient, 27 years of age, was diagnosed with acute myeloid leukaemia and was treated with Idarubicin. After drug was administered, patient experienced the following side effects: anaemia, enterocolitis, eye disorder, febrile neutropenia, ileus, klebsiella sepsis, liver function test abnormal, lung consolidation. Idarubicin dosage: (16 MG, DAILY), INTRAVENOUS. During the same period patient was treated with CYTARABINE, ETOPOSIDE. Patient recovered.